Placeholder Photo

Nevan Elam

Mr. Elam is a native of Silicon Valley who has been managing and advising healthcare and technology companies in the US and Europe for more than 30 years.
Prior to founding Rezolute, Mr. Elam served in various senior leadership roles at different organizations including as Head of the Pulmonary Business Unit at Nektar Therapeutics (NASDAQ: NKTR). During his tenure at Nektar, he was instrumental in streamlining the organization and reshaping its pipeline. Prior to negotiating the sale of his division to Novartis, Mr. Elam spun two entities out of Nektar, including Pearl Therapeutics which was acquired in 2013 by AstraZeneca, for $1 billion.
Earlier in his career, Mr. Elam was CFO and co-founder of a web-based IT platform company serving the electronics and healthcare industries where, in addition to managing finance and business development, he established operations in the US as well as throughout Asia.
In the 1990s, Mr. Elam was a corporate partner at the law firm of Wilson Sonsini Goodrich & Rosati, where he advised domestic and ex-US healthcare and technology companies on various matters from debt and equity financings to licensing and cross-border transactions. His clients included emerging growth companies as well as mature corporations such as Genentech and Hewlett Packard. Notably, he represented Steve Jobs’ company, Next and negotiated the sale of Next to Apple in 1997.
Throughout his career, Mr. Elam has served on the board of directors of different healthcare companies and he currently serves on the board of Savara, Inc. (NASDAQ:SVRA) in Austin Texas, Peak Bio in Palo Alto California, and on the board of Rezolute.
Mr. Elam received his B.A. from Howard University and his J.D. from Harvard Law School.
Speaking In
2:15 PM - 3:15 PM
Monday, June 5
The market volatility in the last 18 months has made it difficult for public biopharmaceutical…